Role of Sphatik bhasma as haemostatic drug in the Management of Rakta Pradar W.R.T Heavy Menstrual Bleeding
Keywords:Raktapradar, Sphatik bhasma, Heavy menstrual bleeding
Heavy menstrual bleeding or abnormal bleeding is most common problems in females in present era due to improper diet habits, sleeping habits due to increasing degrees of civilisation. There are various treatment on heavy menstrual flow like hormonal replacement therapy where there is hormonal imbalancement, Anti fibrinolytics drugs in dysfunctional uterine bleeding available today. According to Ayurveda it can be correlated with Raktapradar. Various drugs are suggested in raktapradar in classical text. In this study efficacy of Sphatik bhasma (potassium aluminium sulphate also known as potassium alum or potashalum, has a molecular formulae of K2(SO4).Al2(SO4)3.24H2O) as haemostatic drug is observed through clinical trial. The clinical study was conducted on 15 patients having heavy menstrual bleeding. Interventional drug Sphatik Bhasma with pakwa kadali phala (banana or Musa paradisiaca) is administered for 3 days. The clinical assessment was done on the basis of grading criteria of Rakta Pradar like amount and duration of bleeding, pain, burning sensation and weakness and were assessed on mean scores before and after treatment and analysed. The results were statistically and clinically highly significant in Raktapradar.
How to Cite
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.